Multiple Sclerosis Clinical Trial
Intermittent Hypoxia in Persons With Multiple Sclerosis
Summary
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here we aim to look at brain activation and ankle strength before and after AIH so we can gain a better understanding of how the AIH may improve strength in those persons with MS.
Full Description
Recent research has shown that AIH, characterized by brief episodes of reduced oxygen levels in the inspired air, has the potential to induce neural adaptations. These adaptations are suspected to influence several aspects of neuroplasticity, including the modulation of neurotransmitters and neurotrophic factors. Persons with MS typically exhibit greater cortical activation to achieve a given motor task compared to healthy controls, suggesting compensatory activations in motor cortices and the recruitment of additional non-motor regions for successful motor control. Therefore, interventions that promote adaptive neuroplasticity in motor control systems may induce a reduction in fMRI activation during motor tasks as well as an increase in functional connectivity between somatomotor cortices. This study will explore potential mechanisms of this intervention in MS using motor task performance and advanced neuroimaging techniques.
Eligibility Criteria
Inclusion Criteria:
Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
Motor Functional System Scale (FSS) between 2-4
Relapse free for at least 1 year
Age ≥ 18 years and ≤ 75 years
Safe to be scanned based on MRI questionnaire
Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
Exclusion Criteria:
Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
History of epilepsy
Chronic obstructive pulmonary disease
Uncontrolled Sleep apnea
Pregnancy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Chicago Illinois, 60611, United States More Info
Principal Investigator
Sub-Investigator
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.